#ADC

All articles tagged with "ADC"

Daiichi Sankyo reported an extraordinary loss of 149.4 billion yen, roughly $950 million.
The loss was tied to overestimating demand for antibody-drug conjugate manufacturing capacity.
The company is scrapping plans to build that capacity, marking a notable strategic reversal.

DT Editorial Team·May 11, 2026·via endpoints.news

QLS5132 is an investigational ADC targeting CLDN6 in advanced platinum-resistant ovarian cancer.
In a 28-patient phase 1 study, adverse events were common but no treatment-related event caused discontinuation or death.
Researchers say the trial showed an early signal of clinical benefit in a heavily pretreated population.

DT Editorial Team·Apr 20, 2026·via medicalxpress.com